Atara Biotherapeutics (GB:0HIY)

Atara Biotherapeutics (0HIY) Share Price & Analysis


0HIY Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.26 - $5.52
Previous Close$1.47
Average Volume (3M)6.52K
Market Cap
Enterprise Value$47.60M
Total Cash (Recent Filing)$153.79M
Total Debt (Recent Filing)$51.75M
Price to Earnings (P/E)N/A
Nov 07, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares Outstanding101,102,152
10 Day Avg. Volume1,002
30 Day Avg. Volume6,524
Standard Deviation0.20
Financial Highlights & Ratios
Price to Book (P/B)20.07
Price to Sales (P/S)2006.72
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.79
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.16
Price Target Upside1241.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4




What was Atara Biotherapeutics’s price range in the past 12 months?
Atara Biotherapeutics lowest share price was $1.25 and its highest was $5.52 in the past 12 months.
    What is Atara Biotherapeutics’s market cap?
    Currently, no data Available
    When is Atara Biotherapeutics’s upcoming earnings report date?
    Atara Biotherapeutics’s upcoming earnings report date is Nov 07, 2023 which is in 35 days.
      How were Atara Biotherapeutics’s earnings last quarter?
      Atara Biotherapeutics released its earnings results on Aug 08, 2023. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.656 by -$0.024.
        Is Atara Biotherapeutics overvalued?
        According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Atara Biotherapeutics pay dividends?
          Atara Biotherapeutics does not currently pay dividends.
          What is Atara Biotherapeutics’s EPS estimate?
          Atara Biotherapeutics’s EPS estimate is -$0.62.
            How many shares outstanding does Atara Biotherapeutics have?
            Currently, no data Available
            What happened to Atara Biotherapeutics’s price movement after its last earnings report?
            Atara Biotherapeutics reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.656. Following the earnings report the stock price went down -15.285%.
              Which hedge fund is a major shareholder of Atara Biotherapeutics?
              Among the largest hedge funds holding Atara Biotherapeutics’s share is Baupost Group LLC. It holds Atara Biotherapeutics’s shares valued at 16M.


                Atara Biotherapeutics Stock Smart Score

                The Atara Biotherapeutics Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Atara Biotherapeutics

                Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Atara Biotherapeutics
                Allogene Therapeutics
                Crispr Therapeutics AG
                Editas Medicine
                Gilead Sciences

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis